# A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

> **NCT07078604** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 20 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **BIOLOGICAL:** CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
- **DRUG:** Chemotherapy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Computed Tomography Assisted Biopsy
- **BIOLOGICAL:** Sargramostim
- **PROCEDURE:** Ultrasound-Guided Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Positron Emission Tomography (PET)

## Key facts

- **NCT ID:** NCT07078604
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07078604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07078604, "A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07078604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*